Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

Biocon added 1.36% to Rs 325.25 after the company announced that its subsidiary, Biocon Biologics (BBL), has launched YESINTEK (ustekinumab-kfce) in the United States.

Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the red. Nifty 50 closed at 22,552.50, while ...

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Shares of firms like Biocon, LIC, NTPC Green, IREDA, Texmaco Rail, and others will be in focus on Tuesday's trade ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Stocks like Welspun Corp, SBI Life Insurance Company, Oil and Natural Gas Corporation, NTPC, Waterbase, Shree Cement, Refex ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to ...